Nature aging|2025|Feldman H et al.|2 citations
PMID: 40983695
A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
BACKGROUND: While glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated benefits in reducing complications following total knee and hip arthroplasty, their effects in spinal surgery remain unclear. Prior studies have reported mixed…
Excess or dysfunctional adipose tissue is a key pathophysiological factor in cardiovascular-kidney-metabolic syndrome. However, until very recently, there was no evidence that pharmacological treatments for obesity could significantly impact major ca…
BACKGROUND CONTEXT: Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has shown efficacy in managing glycemic control and obesity but its effects on surgical outcomes, particularly in posterior cervical fusion (PCF), are underexplored.…
INTRODUCTION: The PIONEER REAL Italy study examined the clinical outcomes associated with oral semaglutide in real-world settings. METHODS: This was a multicenter, prospective, non-interventional, single-arm study in adults with type 2 diabetes (T2D)…
BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), improves metabolic health and reduces liver fat in people with HIV (PWH) and metabolic dysfunction-associated steatotic liver disease (MASLD). Whether changes in epigenet…
INTRODUCTION: Perioperative bronchoaspiration is a serious complication often associated with inadequate fasting or delayed gastric emptying, including that caused by glucagon-like peptide-1 receptor agonists (GLP-1-RAs). Despite growing semaglutide…
BACKGROUND: Coronary artery disease (CAD) imposes marked morbidity on patients, with many afflicted with debilitating residual symptoms despite optimal application of the available medical and surgical options. Glucagon-like peptide-1 (GLP-1) agonist…
PURPOSE: Glucagon-like peptide-1 receptor (GLP-1R) agonists exert multiple beneficial effects. However, their effects on reproduction system are controversial. Here, we aimed to investigate their effects on male reproduction and provide safety eviden…
BACKGROUND: Idiopathic intracranial hypertension (IIH) is a debilitating neurologic condition marked by elevated intracranial pressure (ICP), typically affecting obese women of reproductive age. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs),…
BACKGROUND: Recent randomized controlled trials (RCTs) have investigated glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual or triple co-agonists for weight loss among adults with overweight or obesity and without diabetes. PURPOSE: To as…
BACKGROUND: Semaglutide, a GLP-1 receptor agonist (GLP-1RA), has shown potential in controlling type 2 diabetes due to their ability to lower blood glucose and improve cardiovascular outcomes. Although semaglutide is the newest GLP-1RA available, its…
The rise of compounded weight-loss drugs has emerged as a pressing global health issue, threatening consumers and health-care systems. Factors fueling this crisis include the desire for rapid weight-loss options, inadequate regulatory frameworks, and…
BACKGROUND: The increasing use of glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide, for weight management has raised new considerations in aesthetic surgery. While these drugs offer significant preoperative weight loss benefits,…
Metabolic dysfunction associated steatohepatitis (MASH), formerly known as NASH, represents one of the leading causes of chronic liver disease worldwide. Its high prevalence is driven by insulin resistance, obesity and type 2 diabetes (T2D) and is as…